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Abstract: This study aim was to compare the therapeutic efficacy of Curosurf and Survanta in preterm infants which 
were admitted into NICU. In this interventional study, 150 preterm infants divided randomly in two groups (75 in 
Survanta and 75 in Curosurf). Data analyzed by statistical methods in SPSS.19. The significance level was considered to 
be P<0.05.There were no statistically significant differences in gestational age, birth weight, mortality rate, 
pneumothorax, Brunch-Pulmonary Dysplasia (BPD), Intra Ventricular Hemorrhage (IVH) and the mean duration of 
hospitalization between two groups. But in repeating dose of Survanta group with 67.7% was higher than Curosurf group 
with 32.3% (p=0.043) and in mean duration of ventilation Survanta group with 8 days was lower than Curosurf group 
with 10.5 days (P=0.001). Results showed in treatment of RDS in preterm infants each of two groups had similar side-
effects but the need for repeated doses in Curosurf group and need for ventilation in Survanta group is less than others . 
 




Respiratory distress syndrome (RDS) is observed in 
prematurely born infants and as a common cause of 
morbidity and mortality in preterm infants; a defect in the 
development of the lung is usually seen in preterm birth 
and occurs due to lack of surfactant (Ma et al., 2012). 
 
Respiratory distress syndrome deal to mortality in preterm 
infants; thus, surfactant replacement of surfactant has 
been the only effective and important treatment for 
Respiratory distress syndrome and has decreased the 
pneumothorax and mortality rates of preterm infants with 
Respiratory distress syndrome. Recently the effectiveness 
of surfactants has been performed by many studies and 
meta-analyses (Jeon et al., 2015). 
 
Pulmonary surfactant deficiency leads to extensive 
atelectasis, the disappearance of the remaining lung 
capacity and disorient the ratio of ventilation for 
perfusion. The consequences of this state, is weakness of 
the respiratory muscles and decreased pulmonary 
compliance which associated with reduced oxygenation, 
cyanosis, respiratory and metabolic acidosis and with 
increased pulmonary vascular resistance and right to left 
shunt through the duct lead to more hypoxemia (Engle et 
al., 2008; Shahfarhat et al., 2006). 
 
Some studies showed that preterm infants before 32 
gestational age have structurally immature lungs at the 
secular stage of development and the surface area and 
diffusion distance for gas exchange are not normal 
(Fujiwara et al., 1980; Halliday et al., 2005). 
 
The surfactant replacement was firstly reported by 
Fujiwara, et al and then many subsequent trials have been 
performed with other types of natural surfactants contain 
foreign proteins that may be potentially immunogenic and 
infectious (Fujiwara et al., 1980; Obladen et al., 2005; 
Moya et al., 2009). 
 
This syndrome occurs in 60-80 % of infants with lower 28 
week, 15-30% in 32-36 week and 5% in upper than 36 
week. The disease despite treatments, maintenance and 
support measures the causes of 50 percent of all deaths in 
the neonatal period. In recent years, various types of 
surfactant administration, as lifesaving treatment or 
prevention of mortality in these patients has opened a 
window of hope (Shahfarhat et al., 2006). 
 
There are three commonly researched natural surfactants 
and many RCT studies in the world showed that 
surfactant replacement therapy has an important role in 
the prevention or treatment of RDS (Soll et al., 2009; 
Cummings et al., 1992; Logan et al., 2009; Egberts et al., 
1993; Zola et al., 1993; Onrust et al., 1999). 
 
Surfactants are generally reduced mortality from RDS, 
especially if combined with administration of antenatal 
corticosteroids (Khalessi et al., 2006).  
 
Short-term effects of surfactant administration, including 
improved oxygen gradient of alveolar - arterial, lower 
mean airway pressure (MAP), reducing the need for 
ventilation, increased lung compliance, reduce the 
incidence of pneumothorax and improvement pulmonary 
symptoms in the Chest x-ray (Engle et al., 2008; Halliday 
et al., 2005; Behrman et al., 2000). 
 
These drugs have side effects such as hypoxia, 
bradycardia, increasing carbon dioxide partial pressure, *Corresponding author: e-mail: manouchehrbarak@gmail.com
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transient decreasingthe brain activity and cause bleeding 
in the lungs but they doesn’t decrease the Broncho - 
Pulmunary Dysplasia (BPD) (Behrman et al., 2000). 
 
Important role of surfactants in the prevention and 
treatment of RDS is reducing the surface tension in the 
alveoli (Khalessi et al., 2006). 
 
Baroutis and et al in study compared the efficacy of three 
surfactant and showed that Curusurf due to less duration 
of artificial respiration, supplemental oxygen and hospital 
stay were better than others (Proquitte et al., 2007). 
 
Ramanathan and et al in a study showed that the marked 
reduction in FiO2 was seen in Curosurf group compare to 
the Survanta group (Ramanathan et al., 2004). 
 
Considering the different types of this medication and 
complications related to each one, the aim of this study 
was to compare the effect of two types of surfactant 
(Survanta and Curosurf) in reducing morbidity and 
mortality in preterm infants with RDS admitted to the 
NICU of the Ardabil hospitals in 2010-13. 
 
MATERIALS AND METHODS 
 
This is an interventional study that has been done on 
preterm infants with gestational age <37 week and has 
HMD. The infants selected by doctor diagnosis, ABG and 
Chest x-ray, symptoms and clinical signs and need for the 
artificial respiration. Of patients fulfilled inclusion 
criteria, 150 preterm infants selected randomly and after 
blinding divided in two groups and each one receive one 
type of surfactant (Curosurfor Survanta). Two groups 
were matched by Gestational age, type of delivery, sex 
and birth weight. Infants with meconium aspiration 
syndrome, congenital anomalies, deadly diseases, 
metabolic diseases, sepsis or other infections, and babies 
who underwent resuscitation in the delivery room were 
excluded from the study. The design of this study was 
evaluated and approved by the ethical committee of 
Ardabil University of Medical Science. Necessary 
information about the side effects such as: BPD (oxygen 
dependency at 28 days), bleeding into the brain ventricles 
(IVH), pneumothorax, repeating medication, length of 
stay in hospital and ventilation time were registered for 
both group in a checklist. In each group, the required dose 
(100mg/kg) was administered by injection at the distal 
tracheal tube and until two hours late the endotracheal 
suction was not done. During administration time and 
then, infants were monitored and controlled by Pulse 
Oximetry, arterial blood gas tests and repeated 
examinations. Data analyzed by statistical methods in 





Of all patients 70 (46.7%) were boy and rest of them were 
girls. The mean gestational age in boys and girls were 
29.74 and 29.58 week; respectively. The mean of 
ventilation time in boys and girls were 11.77 and 11.65 
day; respectively.  
 
Of all infants, 28(18.67%) were died, 14.7% have 
intraventricular hemorrhage, 16.7% have Pneumothorax 
and 12% have BDP but the differences between two 
groups wasn’t statistically significant. 
 
Results showed that there wasn’t a significant difference 
in gestational age and birth weight between two groups, 
so we can say that two groups were matched by 
gestational age and birth weight. The mean of ventilation 
time in Surfactant Survanta group significantly lower than 
Curosurf group (p=0.001). The average of hospitalized 
time in Surfactant Curosurf group was lower than 




Currently one of standard treatments for sever RDS and 
requiring ventilators, is Surfactant administration. In 
Proquitte study in infants’ clinic in Berlin hospital, there 
wasn’t significant difference in Fio2, Blood gas, BPD 
incidence in 28 day, IVH, Pneumothorax, PDA and 
mortality between two groups. Lower incidence rate of 
NEC in Survanta group compare with Curosurf was not 
statistically significant. Also, there was not any significant 
difference in mortality, side effects due to Survanta and 
Curosurf such as IVH, BPD and PTX in this study. In our 
study the rate of mortality in Survanta and Curosurf was 
20% and 17.3%; respectively which was similar to other 
studies and this could represent a qualitative and 
quantitative improvement of nursing services, closer to 
standard criteria similar to developed countries (Proquitte 
et al., 2007). 
 
In Ramanathan and et al study in South California, the 
efficacy of two Surfactant (Survanta and Curosurf) for 
RDS was cheeked and results showed that the mean of 
Fio2 in Curosurf group was lower than Survanta 
(P=0.005) and in neonates with gestational age lower than 
32 or 36 week the rate of mortality in Curosurf was 
significantly lower than Survanta group (P=0.034) 
(Ramanathan et al., 2004). 
 
In a retrospective multicenter done by Trembath and et al 
, results showed that there were not any differences in air 
leak syndromes, BPD, NEC, IVH (grade III or IV), and 
mortality between two surfactants (Trembath et al., 2013). 
Also, in this study the need for repeated dose in Survanta 
group was more than Curosurf (P=0.043) and there wasn’t 
any significant difference between mortality and 
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Surfactant type. Which our study result in this matter was 
similar to other studies (Baroutis et al., 2003; Kamrani et 
al., 2008).  
 
In Clark and et al study in Florida, there wasn’t any 
significant differences in mortality rate, side effects, NEC 
and bleeding into the brain between two Surfactant 
(Infasurf and Survanta) (Clark et al., 2001) which was 
similar to our study results, because the Surfactant type 
hasn’t significant effect on decreasing mortality rate and 
side effects and this result confirmed by other studies 
(Trembath et al., 2013;Baroutis et al., 2003; Clark et al., 
2001; Singh et al., 2011).Singh and et al in a study 
showed that high dose of Curosurf administration 
compare to Survanat due to low mortality and need for 
repeated dose (Singh et al., 2011). 
 
Fujii and et al in study showed that in Curosurf group the 
need for repeated dose, low ventilation duration, sooner 
effect and more survival rate is higher than another group 
(Fujii et al., 2010). 
 
In current study, the need for repeated dose in Survanta 
group was more than Cursurf (p=0.043) and also, the 
ventilation time in Survanta group was lower than 
Curosurf group. (p=0.001) The mean of hospitalization 
duration in Curosurf group same as Survanta group which 
was similar to Saeidi and et al study but not similar to 
Kamrani et al study (Baroutis et al., 2003; Kamrani et al., 




Results showed that using two standard drugs (Survanta 
and Curosurf) in patients with HMD have similar side-
effects. For need to low repeated dose we must use 
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